RE:Roche anti-TIGIT hope turns to Tecentriq
January 09, 2024 - Coherus BioSciences axes TIGIT.
Coherus’ decision to cut its losses follows a series of events that have caused confidence in TIGIT, a target that was once a hot property, to ebb and flow. Roche has ridden out setbacks to emerge with evidence that its candidate may improve overall survival in first-line non-small cell lung cancer. Gilead and Merck & Co. have had their own ups and downs, while BMS and Novartis have axed candidates.
https://www.fiercebiotech.com/biotech/coherus-axes-tigit-program-walking-away-junshi-candidate-2-years-after-making-35m-bet